Immunovia’s innovative multiplexing technology (IMMrayTM) uses a single drop of serum to simultaneously measure 400+ biomarkers and provide condensed diagnostic-, prognostic- and predictive biomarker signatures.The companyImmunovia has been a listed company since 2015, with shares (as IMMNOV), traded on Nasdaq First North in Stockholm and now heading for the Nasdaq Stockholm main-list (Q1 2018). The company has 40+ employees, is headquartered in Lund, Sweden; and is currently setting up reference labs in both Lund, Sweden, and Boston, USA.Technology IMMray™ is a versatile and robust platform technology for performing clinical serum proteomics, developed and optimized over 17 years at Lund University/Create Health. In contrast to genomics microarray technologies (e.g. NGS) that measure the potential risk of a future disease/drug (Rx) response, IMMray™ multiplexes the patient serum proteome and assesses the actual current state of the disease/treatment response. The arrays are developed from a proprietary set (currently 970) recombinant single chain fragment variant (scFV) antibodies from our own phage-display library and are able to detect changes in immuno-regulatory factors, cytokines, enzymes, complement proteins, innate factors, and cancer associated proteins.Diagnostic workflowIMMray™ is optimized for routine diagnostic lab workflows with three day’s turnaround time (TAT) from patient sample received to test report.Disease areasIMMrayTM has shown its applicability within two main disease areas – oncology (pancreatic) and autoimmune s (rheumatoid arthritis, Systemic Lupus Erythematosus, vasculitis, Sjogrens Syndrome). The key advantages, using IMMrayTM includes the ability to work with serum samples as opposed to biopsies, and, the achievement of very high clinical sensitivities and specificities to successfully differentiate between phenotypically similar indications.Our pharma offerings For our pharma partners, we design Customized Discovery Chips and IMMray™ CDx Test solutions for patient cohort dichotomization. After an initial survey of our 400+ serum biomarkers, we use our proprietary bioinformatics tools to derive a specific condensed signature/algorithm of 5-35 proteins capable of differentiating patients into sub-cohorts. This enables patient selection with sensitivities and specificities above 95%. Initially, IMMray™ product testing will be performed through our reference laboratories in Lund, Sweden and Boston, USA.